Chemistry:Fluetonitazene
From HandWiki
Fluetonitazene (fluornitrazene, F-etonitazene, 2-fluoroetonitazene) is a benzimidazole derivative which is an opioid designer drug. It was patented in 2024 as a potential novel analgesic,[1] but appeared on the illicit market at around the same time, first being identified in Germany in March 2024.[2][3] It is a potent opioid agonist in vitro with similar potency to N-Desethyletonitazene.[4]
See also
- Fluetonitazepyne
- Isotonitazene
- Protonitazene
- List of benzimidazole opioids
References
- ↑ Michaelides M, Gomez JL, Rice KC, Sulima A, Baumann MH, "Fluorinated mu-opioid receptor agonists", WO patent 2024/196438, published 26 September 2024
- ↑ "Fluetonitazene". EU Early Warning System Formal Notification. European Union Drugs Agency (EUDA). 14 May 2024. https://workpage.ews-nfp.bg/wp-content/uploads/2024/05/EU-EWS-RCS-FN-2024-0011_fluetonitazene.pdf.
- ↑ "Increasing availability of nitazenes calls for global response". Early Warning Advisory (EWA). United Nations Office on Drugs and Crime (UNODC). February 2025. https://www.unodc.org/LSS/Announcement/Details/b47cf39e-f557-4001-98a8-536af5673e9e.
- ↑ "Pharmacology of newly identified nitazene variants reveals structural determinants of affinity, potency, selectivity for mu opioid receptors". Neuropharmacology 276. September 2025. doi:10.1016/j.neuropharm.2025.110512. PMID 40374158.
 |  |
